| [1] Igene H. Global health inequalities and breast cancer: an impending public health problem for developing countries[J]. Breast J, 2008, 14(5):428-434.[2] Chia S, Norris B, Speer C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers[J]. J Clin Oncol, 2008, 26(35): 5697-5704.[3] Planas-Silva M D, Bruggeman R D, Grenko R T, et al. Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer[J]. Exp Mol Pathol, 2007, 82(1): 85-90.[4] Fujita T, Ikeda H, Kawasaki K, et al. Clinicopathological relevance of UbcH10 in breast cancer[J]. Cancer Sci, 2009,100(2):238-248.[5] Berlingieri M T, Pallante P, Sboner A, et al. UbcH10 is overexpressed in malignant breast carcinomas[J]. Eur J Cancer, 2007,43(18):2729-2735.[6] Wang S, Chen C, Meng Y, et al. Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody [J]. Cancer Lett,2012,325(12):214-219.[7] Tinnikov A A, Yeung K T, Das S, et al. Identification of a novel pathway that selectively modulates apoptosis of breast cancer cells[J]. Cancer Res, 2009, 69(4):1375-1382.[8] Nemolato S, Cabras T, Fanari M U, et al. Thymosin beta 4 expression in normal skin, colon mucosa and in tumor infiltrating mast cells [J]. Eur J Histochem,2010,54(1):e3.[9] Soto E, Yanagisawa M, Marlow L A, et al. P120 catenin induces opposing effects on tumor cell growth depending on E-cadherin expression[J]. J Cell Biol, 2008,183(4):737-749.[10] Valderrama F, Thevapala S, Ridley A J. Radixin regulates cell migration and cell-cell adhesion through Rac1[J]. J Cell Sci, 2012, 125(Pt14):3310-3319.[11] Pallante P, Malapelle U, Berlingieri M T, et al. UbcH10 overexpression in human lung carcinomas and its correlation with EGFR and p53 mutational status[J]. Eur J Cancer,2012,(12):784-788.[12] Fujita T, Ikeda H, Taira N, et al. Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer [J]. BMC Cancer, 2009,9:87.[13] Guerriero E, Ferraro A, Desiderio D, et al. UbcH10 expression on thyroid fine-needle aspirates [J]. Cancer Cytopathol, 2010, 118(3):157-165.[14] van Ree J H, Jeganathan K B, Malureanu L, et al. Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation [J]. J Cell Biol, 2010, 188(1):83-100.[15] Rho J H, Qin S, Wang J Y, et al. Proteomic expression analysis of surgical human colorectal cancer tissues: up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer[J]. J Proteome Res, 2008, 7(7): 2959-2972.[16] Chen T C, Sakaki T, Yamamoto K, et al. The roles of cytochrome P450 enzymes in prostate cancer development and treatment [J]. Anticancer Res, 2012, 32(1): 291-298.[17] Munoz U, Puche J E, Hannivoort R, et al. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1[J].Mol Cancer Res, 2012, 10(9):1216-1227.[18] Kainz B, Shehata M, Bilban M, et al. Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia [J]. Int J Cancer, 2007, 121(9):1984-1993. |
